The Clinicopathological Characteristics of Small Intestinal Neuroendocrine Neoplasms: A Multicenter Retrospective Study from China Abstract #1660

Introduction: Small intestinal NEN (SI-NEN) is much rarer in Asian countries. Hence, the clinicopathological characteristics of SI-NEN are still unknown in Asian population.
Aim(s): To investigate the clinicopathological features of SI-NEN in Chinese patients.
Materials and methods: Clinical data of 277 patients with SI-NEN were retrieved from eleven hospitals respectively located in north, middle, west, east and south of China. Kaplan-Meier analysis was applied to evaluate the overall survival of SI-NEN patients.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Jie Chen

To read results and conclusion, please login ...

Further abstracts you may be interested in

#20 Paraneoplastic antigen Ma2 (PNMA2) auto-antibodies as biomarkers for early small intestine neuroendocrine tumors detection
Introduction: Small intestine neuroendocrine tumors (NETs) comprise well-differentiated NET (benign carcinoid), well-differentiated neuroendocrine carcinoma (malignant carcinoid) and poorly differentiated neuroendocrine carcinoma (NEC). The majority of NET patients have developed liver metastases at the time of diagnosis and surgery is then seldom curative. Novel predictive, diagnostic and prognostic markers are thus needed to improve our capabilities to diagnose and cure these tumors. We have previously identified six novel marker genes for neuroendocrine tumor cells by using Affymetrix microarrays and advanced bioinformatics. One of this markers, the paraneoplastic antigen Ma2 (PNMA2), which is normally expressed only in nervous tissue, can in the process of carcinogenesis be detected in tumors located outside the nervous system. The finding that Ma2 is expressed in small intestine neuroendocrine primary tumors and their metastases made it interesting to screen whether antibodies against Ma2 are present in the serum of NET patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: PhD Valeria Giandomenico
Authors: Cui T, Elgue G, Li S C, Hurtig M, ...
#106 Gastroenteropancreatic neuroendocrine tumors: single institution clinicopathological study
Introduction: Neuroendocrine cells are widely distributed throughout the body, and neoplasms from these dispersed cells can arise at many sites. They are distinguished into two broad categories: 1) Tumors identified as small cell lung carcinomas with biology and natural history of a high-grade malignancy and characteristics of small cell undifferentiated or anaplastic appearance by light microscopy. The WHO categorizes these tumors as poorly-differentiated neuroendocrine carcinomas; 2) Well-defined neuroendocrine tumors (NETs) with variable, but most lyindolent biologic behavior and characteristic well-differentiated histologic features. The majority arise in the gastrointestinal tract and collectively they are referred as gastroenteropancreatic neuroendocrine tumors (GEP/NETs). They include carcinoid tumors, pancreatic islet cell tumors (gastrinoma, insulinoma, glucagonoma, VIPoma, somatostatinoma), paragangliomas, pheochromocytomas, and medullary thyroid carcinomas. The WHO classifies the GEP/NETs as well-differentiated NETs (carcinoid tumors) if they are noninvasive and have benign behavior or uncertain malignant potential. In contrast, GEP/NETs with characteristics of low-grade malignancy with invasion of the muscularis propria or beyond, or metastases, are characterized as well-differentiated neuroendocrine carcinomas (malignant carcinoids). Pancreatic islet cell tumors, whether functioning or not, are classified as well-differentiated NETs or well-differentiated neuroendocrine carcinomas, due to the (depending on) histologic characteristics. The WHO classification for gastroenteropancreatic NETs based on stage (ie size and presence of metastases) and grade (mitotic rate, perineural and lymphovascular invasion, Ki-67 proliferative index) categorizes them as well-differentiated NETs, e.g., carcinoid tumors, or as well-differentiated neuroendocrine carcinomas.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Michael M. Vaslamatzis
#344 Cell Cycle Phase Expression Profile Guided Selection of Proliferative Markers for Well-differentiated Small Intestinal Neuroendocrine Neoplasms
Introduction: Grading of neuroendocrine lesions is often determined by Ki-67 (immunostain), despite limited prognostic ability for this cell cycle marker in well-differentiated tumors (WDNETs) and carcinomas.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Mark Kidd
Authors: Lawrence B, Kidd M, Alaimo D, Svejda B, ...
#355 MicroRNA Signatures as Novel Biomarkers in Small Intestine Neuroendocrine Tumors
Introduction: Small intestine (SI) neuroendocrine tumors (NET) arise from serotonin-producing intraepithelial cells in the SI referred to as enterochromafin cells. The detection of SI-NETs is often concomitant with the appearance of hepatic metastasis thus most patients with SI-NET have metastases at initial presentation. MicroRNAs (miRs) are post-transcriptional key regulators in tumorigenesis which regulate expression of other genes. Little evidence of miR expression or deregulation in SI-NETs has been reported.
Conference:
Category: Basic
Presenting Author: Su-Chen Li
Authors: Li S C, Ahmed E, Martijn C, Lloyd R, ...
#424 Role of MicroRNAs in Small Intestine Neuroendocrine Tumors
Introduction: Small intestinal neuroendocrine tumors (SI-NETs) arise from enterochromaffin cells, which belong to the endocrine system. MicroRNAs (miRs) are post-transcriptional regulators. They control multiple biological processes often functioning either as tumor suppressor genes or oncogenes.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Su-Chen Li
Authors: Li S C, Martijn C, Essaghir A, Lloyd R, ...